Eisai Gets U.S. Priority Review For Drug For Advanced Breast Cancer
This article was originally published in PharmAsia News
Executive Summary
Eisai has achieved a priority review by the U.S. FDA for its E7389 (eribulin) drug for treating advanced breast cancer